Unique Ingredient Identifier D9C330MD8B is listed as a ingredient substance
| RN | 25086-89-9 |
| NCIT | C80921 |
| MF | Polymer substance not supported |
UNII D9C330MD8B COPOVIDONE K25-31 is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| ORAL | CAPSULE | 224.4 mg |
| ORAL | CAPSULE, COATED PELLETS | 11.03 MG |
| ORAL | CAPSULE, DELAYED RELEASE | 33.2 MG |
| ORAL | CAPSULE, EXTENDED RELEASE | 85.55 MG |
| ORAL | SUSPENSION | 21.5 MG/5ML |
| ORAL | TABLET | 849.2 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 2.5 MG |
| ORAL | TABLET, CONTROLLED RELEASE | 5 mg |
| ORAL | TABLET, DELAYED RELEASE | 42 MG |
| ORAL | TABLET, EXTENDED RELEASE | 75 MG |
| ORAL | TABLET, FILM COATED | 853.8 MG |
| ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 20 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING | 4.38 MG |
| ORAL | TABLET, SUSTAINED ACTION, FILM COATED | 6.1 MG |